Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand, sending shares in the British pharmaceutical company down 3% in U.S. trading Wednesday. GSK, which had ...

The Kisqali, if you go back to Slide 9 ... But of course, if you look at the GSK Oncology acquisitions, if you look at ...

Oct 29 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and ...

Despite these positive results, the company’s future growth appears limited by a lack of near-term catalysts and uncertainties surrounding ongoing patent litigation, particularly the Kisqali patent ..

GSK said it is mak­ing its largest man­u­fac­tur­ing in­vest­ment in the US yet, al­lo­cat­ing $800 mil­lion to up­grade its vac­cine pro­duc­tion site in Penn­syl­va­nia. … ...

GSK has made its largest-ever single manufacturing investment in the US. Image credit: Shutterstock/ Golden Shrimp. Following outlays for sites in the UK and Belgium earlier this year, GSK is planning ...

THE ARM FOR THE LANCASTER COUNTY ECONOMY. THIS IS FOR GSK, THE LARGEST INVESTMENT IN MANUFACTURING WE’VE EVER DONE IN THE UNITED STATES. THE $800 MILLION WILL BE USED TO EXPAND GSK’S MARIETTA ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

GSK plans to invest $800 million in its East Donegal Township vaccine packaging facility over the next four years in an expansion project that would add research and manufacturing capabilities ...